Skip to main content
Premium Trial:

Request an Annual Quote

Curtis Keith, Dave Tapolczay

Premium
Harvard University’s Office of Technology Development said this week that it has appointed Curtis Keith as chief scientific officer for the Accelerator Fund.
 
Keith will manage the life science R&D projects supported by the Accelerator, including ensuring that funded projects stay on course and meet development milestones. He joins Harvard’s OTD from CombinatoRx, where he served as co-founder and senior vice president of research. He obtained a PhD in chemistry and chemical biology and an MA in chemistry from Harvard, and holds a BS in biochemistry from McGill University.
 

 
Dave Tapolczay has been named the new director of MRC Technology, the tech-transfer company of the UK Medical Research Council.
 
Tapolczay previously worked as vice president of technology development at GlaxoSmithKline Pharmaceuticals, and has also served as CEO of StylaCats and Pharmophix.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.